FC25: Where Oral Therapies Fit in an Injectable Landscape for Psoriasis Management: An Online Activity

Join our experts for a deep dive into the future of oral therapies in psoriasis, including an oral IL-23 systemic. This session from the 2025 Fall Clinical Dermatology Conference® will cover the safety and efficacy of emerging oral IL-23 inhibitors and how they fit into the evolving treatment landscape and targets.

“The International Psoriasis Council (IPC) has said that we (clinicians) are not doing a good enough job; we are holding on to our systemic therapies like gold and only giving them out when you absolutely prove that you’re worthy… There are other patients who are systemic-worthy.” – Linda Stein Gold, MD

FC25: Where Oral Therapies Fit in an Injectable Landscape for Psoriasis Management: An Online Activity

This activity is supported by an educational grant from Johnson & Johnson.